论文部分内容阅读
目的:探究百令胶囊联合厄贝沙坦片对膜性肾病患者基质金属蛋白酶-9、3和金属蛋白酶组织抑制物-1影响。方法:收集我院肾内科收治的膜性肾病患者98例,根据随机对照表分为对照组和试验组,每组49例。对照组给予厄贝沙坦片治疗,试验组联合百令胶囊治疗。对比分析两组患者的临床疗效、血清Scr、BUN、UA、Ccr、尿蛋白、MMP-9、MMP-3及TIMP-l水平以及不良反应的发生情况。结果:治疗后,对照组临床总有效率为81.63%,显著低于试验组的95.92%(P<0.05)。两组治疗后血清Scr、BUN、UA、MMP-9、MMP-3、TIMP-l水平均显著降低,且试验组显著低于对照组(P<0.05),Ccr水平升高,且试验组显著高于对照组(P<0.05)。对照组不良反应发生率为10.20%,试验组为6.25%,差异无统计学意义(P>0.05)。结论:百令胶囊联合厄贝沙坦片对膜性肾病患者的临床疗效显著,安全性较高,可能与其显著降低MMP-9、MMP-3和TIMP-1水平有关。
Objective: To investigate the effect of Bailing capsule combined with irbesartan tablets on MMP-9 and MMP-1 in patients with membranous nephropathy. Methods: A total of 98 patients with membranous nephropathy admitted to our department of nephrology were enrolled. According to the randomized control table, they were divided into control group and experimental group, with 49 cases in each group. The control group received irbesartan tablets treatment, the experimental group combined with Bailing capsule treatment. The clinical efficacy, serum Scr, BUN, UA, Ccr, urinary protein, MMP-9, MMP-3 and TIMP-1 levels and the incidence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the control group was 81.63%, which was significantly lower than that of the experimental group (95.92%, P <0.05). The levels of Scr, BUN, UA, MMP-9, MMP-3 and TIMP-1 in the two groups were significantly decreased after treatment, and the levels of Ccr in the experimental group were significantly lower than those in the control group (P < Higher than the control group (P <0.05). The incidence of adverse reactions in the control group was 10.20% and in the experimental group was 6.25%, the difference was not statistically significant (P> 0.05). Conclusion: The clinical effect of Bailing capsule combined with irbesartan tablets on patients with membranous nephropathy is significant and safe, which may be related to its significant reduction of MMP-9, MMP-3 and TIMP-1 levels.